Partnerships

Agreement with Helmholtz Centre for Infection Research

Posted on
helmholtz collaboration with Pharmacelera

By Melanie Berg – Nov. 30, 2020 Pharmacelera is proud to announce today, that an agreement was reached with Helmholtz Centre for Infection Research (HZI) for a collaboration.   Helmholtz institute for Pharmaceutical Research Saarland (HIPS), which is a branch of the HZI, will utilize PharmScreen®, a field-based high throughput virtual screening software package, to identify […]

Partnerships

PharmScreen for Knime

Posted on
pharmscreen_knime_computer_with_worklow

We are happy to announce that PharmScreen, our virtual screening tool is available for Knime. Knime is a free open-source platform that uses a modular pipeline concept for data analytics, reporting and integration. Knime links different open-source and third-party nodes and workflows, allowing the connection of different tools and methods for the analysis of different […]

Partnerships

Free access to PharmScreen for COVID-19 research

Posted on
covid-19 virus

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 has spread to all countries without exception, affecting not only risk-population but also young people and healthy individuals. At Pharmacelera we want to join the different public and private initiatives to find a treatment that can stop the expansion of the virus. To do so, […]

News

IDIBELL and Pharmacelera sign a research agreement to find new drugs with anticancer applications

Posted on

Researchers at Bellvitge Biomedical Research Institute will develop a research project with the company Pharmacelera to look for new molecules that block the cohesin complex, with applications in several difficult-to-treat cancers, such as myeloid leukemia, glioblastomas, Ewing sarcomas, colon cancer and bladder cancer. The cell cycle research group of the Bellvitge Biomedical Research Institute (IDIBELL), […]